Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.90 USD
-0.07 (-0.58%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $11.89 -0.01 (-0.08%) 5:52 PM ET
2-Buy of 5 2
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Roivant Sciences Ltd. [ROIV]
Reports for Purchase
Showing records 1 - 20 ( 30 total )
Company: Roivant Sciences Ltd.
Industry: Unclassified
Model Update With Readouts Set to Drive Value Inflection
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Brepocitinib, IMVT-1402 Emerging as the Focal Points to the Story; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Top 16 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Takeaways from Our Call with Roivant Management; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
A Big Win for Brepocitinib in NIU Phase 2 and a Big Share Buy-Back; Raise PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Looking for the Capital Allocation Strategy; Price Target Down to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Company: Roivant Sciences Ltd.
Industry: Unclassified
Looking For Roivant''s Next Big Thing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
When Nothing Turns Into $5 Billion in Less Than a Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
2Q Earnings Call Highlights Value of Brepocitinib; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Strong Fourth Quarter for Roivant; PT Up to $18; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
TL1A Data Positions Roivant as a Force in Inflammation and Immunology; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Second Phase 3 Further Confirms Efficacy and Safety Profile of Vtama in Atopic Dermatitis; PT Up to $15; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Takeaways From Our Conversation with Roivant Sciences Management; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
ADORING-2 Sets Up Vtama as Blockbuster in Atopic Dermatitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Vtama Laying the Groundwork for Acceleration; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Roivant?s RVT-3101 Shows Robust Clinical Efficacy in Phase 2b; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Company: Roivant Sciences Ltd.
Industry: Unclassified
Company: Roivant Sciences Ltd.
Industry: Unclassified
Analyst Meeting Offers Here and Now and Tomorrow of the Roivant Portfolio
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D